200 related articles for article (PubMed ID: 35439320)
1. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U; Murai Y; Agama KK; Sun Y; Saha LK; Yang X; Arakawa Y; Gayle S; Jones K; Paralkar V; Sundaram RK; Van Doorn J; Vasquez JC; Bindra RS; Choi WS; Pommier Y
Mol Cancer Ther; 2022 Jul; 21(7):1090-1102. PubMed ID: 35439320
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
Jossé R; Martin SE; Guha R; Ormanoglu P; Pfister TD; Reaper PM; Barnes CS; Jones J; Charlton P; Pollard JR; Morris J; Doroshow JH; Pommier Y
Cancer Res; 2014 Dec; 74(23):6968-79. PubMed ID: 25269479
[TBL] [Abstract][Full Text] [Related]
3. BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Coussy F; El-Botty R; Château-Joubert S; Dahmani A; Montaudon E; Leboucher S; Morisset L; Painsec P; Sourd L; Huguet L; Nemati F; Servely JL; Larcher T; Vacher S; Briaux A; Reyes C; La Rosa P; Lucotte G; Popova T; Foidart P; Sounni NE; Noel A; Decaudin D; Fuhrmann L; Salomon A; Reyal F; Mueller C; Ter Brugge P; Jonkers J; Poupon MF; Stern MH; Bièche I; Pommier Y; Marangoni E
Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075943
[TBL] [Abstract][Full Text] [Related]
4. Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A; Pommier Y
Clin Cancer Res; 2019 Nov; 25(22):6581-6589. PubMed ID: 31227499
[TBL] [Abstract][Full Text] [Related]
5. The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Marzi L; Szabova L; Gordon M; Weaver Ohler Z; Sharan SK; Beshiri ML; Etemadi M; Murai J; Kelly K; Pommier Y
Clin Cancer Res; 2019 Oct; 25(20):6206-6216. PubMed ID: 31409613
[TBL] [Abstract][Full Text] [Related]
6. The novel ATR inhibitor M1774 induces replication protein overexpression and broad synergy with DNA-targeted anticancer drugs.
Jo U; Arakawa Y; Zimmermann A; Taniyama D; Mizunuma M; Jenkins LM; Maity T; Kumar S; Zenke FT; Takebe N; Pommier Y
Mol Cancer Ther; 2024 Mar; ():. PubMed ID: 38466804
[TBL] [Abstract][Full Text] [Related]
7. Antigen-independent tumor targeting by CBX-12 (alphalex
Gayle S; Paradis T; Jones K; Vasquez J; Paralkar VM
Immunotherapy; 2022 Dec; 14(18):1467-1480. PubMed ID: 36597724
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
10. The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
Pommier Y; Cushman M
Mol Cancer Ther; 2009 May; 8(5):1008-14. PubMed ID: 19383846
[TBL] [Abstract][Full Text] [Related]
11. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects.
Pourquier P; Pilon AA; Kohlhagen G; Mazumder A; Sharma A; Pommier Y
J Biol Chem; 1997 Oct; 272(42):26441-7. PubMed ID: 9334220
[TBL] [Abstract][Full Text] [Related]
12. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
13. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
[TBL] [Abstract][Full Text] [Related]
14. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
15. Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin.
Pond CD; Marshall KM; Barrows LR
Mol Cancer Ther; 2006 Mar; 5(3):739-45. PubMed ID: 16546989
[TBL] [Abstract][Full Text] [Related]
16. ATM deficiency results in accumulation of DNA-topoisomerase I covalent intermediates in neural cells.
Alagoz M; Chiang SC; Sharma A; El-Khamisy SF
PLoS One; 2013; 8(4):e58239. PubMed ID: 23626666
[TBL] [Abstract][Full Text] [Related]
17. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
18. Tipin functions in the protection against topoisomerase I inhibitor.
Hosono Y; Abe T; Higuchi M; Kajii K; Sakuraba S; Tada S; Enomoto T; Seki M
J Biol Chem; 2014 Apr; 289(16):11374-11384. PubMed ID: 24573676
[TBL] [Abstract][Full Text] [Related]
19. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
20. Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Drwal MN; Agama K; Wakelin LP; Pommier Y; Griffith R
PLoS One; 2011; 6(9):e25150. PubMed ID: 21966440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
